PlatformQ Health is launching, “Aligned Health Care Provider and Patient Education on Calcitonin Gene-Related Peptide-Targeted Treatment of Migraine,” a new digital tethered education program, produced in collaboration with the American Migraine Foundation and the National Headache Foundation on January 22, 2021.
This program follows the tethered education model with two separate sessions, one for clinicians and one for patients and their caregivers. This model equips patients, caregivers and clinicians with the skills, approaches and best practices needed to support shared decision making and treatment goals.
Patients and caregivers can tune into NeuroCareLive to watch Seeking Migraine Relief with Calcitonin Gene-Related Peptides: What, When, and for Whom? on January 22, 2021 at 10am ET. The 60-minute live and interactive session will be led by Dr. Stewart J. Tepper, Professor of Neurology at the Geisel School of Medicine at Dartmouth, Deborah Henscheid Lorenz, patient advocate and Executive Committee Member with the American Migraine Foundation and the International Headache Society Global Patient Advocacy Coalition along with Nim Lalvani, MPH, Executive Director at the American Migraine Foundation.
Patients and caregivers will be able to gain a deeper understanding of some of the available treatment options for migraine, when to start therapy, and the potential side-effects that can be expected. The experts will also provide tips for how to talk with the doctor and ensure that patients’ and caregivers’ preferences and goals are considered. The education will also help gain access to the support and resources to manage migraines effectively and safely.
Some other topics that will be explored:
- Pathophysiology of migraine, its triggers, and severity
- Traditional management and preventive therapies
- Agents targeting new pathways for migraine
- What to expect on your migraine symptoms and your ability to function
- Shared decision-making
The clinician education activity entitled, “Updates on Calcitonin Gene-Related Peptide-Targeted Therapies for Acute and Chronic Migraine” intends to engage Neurologists, Headache Specialists, Primary Care Physicians, Pain Specialists, Psychiatrists, Nurse Practitioners, Physician Assistants, OB-GYN, Pharmacists, and Nurses who treat or are involved in the treatment of patients with chronic migraines. The 60-minute, interactive and expert-led program will air live on Friday, January 22, 20201 at 3pm ET on NeuroSeriesLive, the leading provider of live, online medical education events for clinicians in neurology.
The session will be streamed live and feature an interactive slide presentation with real-time Q&A led by the expert panelists, Stewart J. Tepper, MD, Professor of Neurology at the Geisel School of Medicine at Dartmouth and Susan Hutchinson, MD, Director at the Orange County Migraine & Headache Center. During the session, they will discuss:
- The underlying pathophysiology of CGRP and its role in the development of migraine
- The relative safety and efficacy of CGRP targeted agents (monoclonal antibodies and small antagonist) for the prevention and the acute treatment of chronic migraine
- CGRP monoclonal antibodies and small molecule antagonist for migraine
- The clinical consequences of nonadherence in patients with migraine and how they may be adequately addressed in clinic
Participants can earn 1 AMA PRA Category 1 Credit™ after completing this activity. Presented by the Albert Einstein College of Medicine-Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC and supported by an educational grant from Allergan.
PlatformQ Health partners with leading health care experts and patient advocacy organizations to produce digital education – including tethered programming – across a range of health topics.